The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
that was one buyer
Im shares bought stateside today
.
@J_CIT
the point is that the data is already there! It ust needs to be analysed properly and publicised properly.
It won't take 5 years or anything like that.
Getting on a large platform trial would be good, but not really necessary imo
If I had to pick a Platform worthwhile it would be remapcap
https://www.remapcap.org
This was posted tonight by well respected, working A&E consultant. He agreed it could be shared. Slightly edited because of size limit.
I still can't get my head around LTH holders selling out at this point . After holding we're possibly 6 weeks away or less from Synairgen unequivocally showing the world that sng001 is a highly effective treatment both IN & OUT of hospital. Oh & we're at a rock bottom SP. Am I missing something?
P3 hospital:
Progression to severe disease
PP
517
32 (12.3%) - placebo
20 (7.8%) - sng
36% risk reduction, p = 0.11
Just consider this. 10% of the entire PP progressed to severe disease. Out of 517 patients, 52 people progressed to severe disease. That means 450 people diluted our results by not progressing to severe disease and made our results insignificant.
The question is can we cut away some of the 450 PP trial participants that are diluting our results without removing those that progressed to severe disease.
From the SG018 Protocol:
The following subgroups will be considered for analysis:
• Age
• comorbidities
• smoking
• Sex
• Race
• Prior duration of symptoms
• BMI
Now the ones who progressed to severe disease are most likely: Elderly, unvaccinated, those with co-morbidities & those who presented late.
It's likely that both young people (under 40s) & people without co-morbidities did not progress to severe disease so we can eliminate those in the subanalysis.
20% of patients fully vaccinated & a further 15% had 1 dose . Considering the vaccine reduces the odds of Progression to severe disease this is another population you could cut out.
Sng can mix and match these to find the perfect fit/population where the most benefit & showed significance.
If you could keep the PP 32 placebo patients who progressed to severe disease & 20 on sng who progressed or even the ITT 46 placebo who progressed & 33 on sng who progressed but cut the trial population down to 300 - 400 the results should show significance. They have a multitude of ways to do that WITH scientific backing I.e natural interferon production is impaired in older people, who have co-morbidities & aren't fully vaccinated (2 dose) which is why when we ran the analysis in this population we found significant results in...
Activ 2:
Hard virological evidence that sng is a potent inhibitor of viral load in the airway. When activ 2 patients use the nebuliser where is sng accumulating the most? The back of the throat. Where are the PCR swabs swabbing to measure viral load for activ 2 study? Back of the throat. Can't see an IV mAb beating that.
Irregardless the market will finally see evidence sng reduces reduces viral load in patients and that sng isn't worth the 7-8p it's valued at now given that the cash value alone of the company is 12.4p.
Throw in terms like viral agnostic, broad spectrum, Sir Stephen Holgate & the share price should be higher than 20 on either of the trial results, let alone both.
GLA
lol indeed!!! The J on my keyboard is a bit sticky.
Just my opinion.
Well spotted
Over the weekend I posted that I was expecting a Poly TR-1 Monday or tuesdy. Well, obviously that was wrong! Hey Ho.
Also, that I would be surprised if a Sprinter or ACTIV2 data RNS didn't apear during the week. Nothing yet, but a couple of dayas to go. Fingers crossed.
But this share never fails to surprise, no matter how much you research and try to understand. Always ust my opinion
GLA
HSD, that will be because Synairgen are still on the trial. It is just paused for now. Probably waiting for a protocol update. We are the only one left on the trial now.
I expect another Poly TR-1 on Monday/Tuesday.
Over £2? hmmm no predictions on that from me.
Towards or Over £1, possibly before the end of March, but that would require very positive results from the deep dive into the Sprinter data and/or Good data from ACTIV2-P2 being released to the company.
Neither situation is guaranteed
read this
We are more effective than anything on the market
Why we are not headline news is just bizarre beyond belief!!
https://www.sciencedaily.com/releases/2022/03/220303125021.htm
rubbish
No they weren’t taken as far as is known. This is one of the big bugbears! Logistically it makes everything a lot more difficult especially in some of the less developed countries where the trial was held so I understand why they weren’t taken
I am pretty sure Activ-2 did have blood samples taken though…
I suppose this post is for folks like Emma(?) and others that may not understand the complexities of clinical trials.
Yes, headline data showed that it did fail to meet statistical significance on the two primary endpoints, but that was when compared to a much improved SOC that did not exist when the P2 Hospital trial was run, and the background of vaccinations that obviously changed the landscape . Having said that, the Primary endpoints were virtually the same as SOC. Conclusions? SNG001 is at least as good as SOC!
The secondary end points were significantly better than SOC.
Progression to serious illness/death within 35d was 36.3% better
Progression to intubation/death within 35d was 32% better
Progression to Death within 35d was 40.5% better!
Conclusion. It works!! Of that there is no doubt. The safety profile alone is immense.
The trial 'failed' for 3 reasons
1. Improved SOC & Vaccinations changed the playing field
2. The trial design was based on the P2 trial and not seriously changed to reflect the new landscape
3. Even though 6 times the size of P2, it was still not powered enough to drive out statistical significance.
NOT because the drug doesn't work, because it obviously does.
The deep dive into the P3 results being undertaken will, I think, drive out some much betteer and statistically significant results. We just have to wait, patiently
Good ACTIV2-p2 data and/or better Sprinter analysis will pave the way to a very quick eUA from FDA.
and there will be a Polygon TR-1 tomorrow :-)
Have a good night
ACTIV2-P3 for synaairgen is still running. It was only the SAB arm that was closed. That leaves us as the 'last man standing' on the ACTIV2 trial
I will believe that until there is an official statement to the contrary.
#SNG the only broad spectrum anti viral left standing! Still on the ACTIV2 P3 trial (unless you know different) The small southampton biotech company with the most effective Covid therapeutic in the world! Amazing! it will be there for any new mutations or virus that emerges????
Deep dive data analysis of the Sprinter trial will throw out some genuine nuggets. ACTIV2 P2 data will show an unblemished safety record, unlike all the other trial drugs that have some mor safety issues! #SNG
I do not understand why people sold, last week or today!
The company is sound, the science is sound, the research done by some very clever people on this board, but mainly elsewhere, is sound.
As tW said "We know it works"
Hold tight
the article only came out at 15:40 gmt. By that time a very large number of PIs had made their choice nd (foolishly) jumped ship
I do not have any need to shout out my history or credentials
I do know just a bit about how clinical trials are run. that is enough.
Good luck
nothing lost until you sell
The company, specifically RM, and Polygon were talking at length over the weekend before Monday's RNS. There is no real surprise about that, it would be strange in the extreme had they not.
Whatever the conversation detail was, it was clear to Polygon, that they are backing a 'potential' winner all the same.
Make your choice
ghia, it was not taken as a dig at all
I absolutely understand that 'a source' or 'word on the street' can be maligned by those that know nothing
There are some in the TG group & the Guild (and possibly the closed reddit group) that do have direct contact with the company at various levels or even RM.
The summary of one of those conversations I posted on Monday